October 09, 2026 08:50 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Restriction, not complete closure’: Supreme Court questions Delhi shutdown ahead of CJP protest | 'Unwarranted': India hits back at JD Vance over ‘indentured servants’ remark amid US Green Card crackdown | US targets Microsoft, Infosys, Tata in green card crackdown | ‘Bold and inventive’: Canadian poet Anne Carson wins 2026 Nobel Prize in Literature | ‘Attempt to destabilise world’s largest democracy’: 42 retired judges rally behind Gyanesh Kumar over ‘vote chori’ row | ‘Vote chor, gaddi chod’: Dhruv Rathee, Prakash Raj join Bengaluru protest against Gyanesh Kumar | India condemns Houthi attacks on Saudi airports, calls targeting of civilian infrastructure unacceptable | Dalal Street bloodbath: Investors lose Rs. 8 lakh crore as Sensex crashes over 1,000 points | Amazon layoffs hit India, US and UK: Fresh job cuts rock e-commerce giant amid festive shopping season | Bollywood mourns Nana Patekar: Anupam Kher, Akshay Kumar, Jr NTR, Suniel Shetty pay emotional tributes

India to begin human trials of COVAXIN next week

| @indiablooms | Jul 07, 2020, at 01:22 pm

New Delhi/IBNS: The human trials of India's first Covid-19 vaccine, COVAXIN, is expected to begin next week, media reports said.

COVAXIN, which has been developed by Hyderabad-based Bharat Biotech International Limited (BBIL), will be tested on more than 1,100 people in phase 1 and 2 clinical trials.

COVAXIN was caught in the midst of a controversy after the Indian Council of Medical Research (ICMR) had partnered with BBIL to fast-track the clinical trials to launch India's indigenous vaccine by Aug 15.

The Indian scientific community has, however, termed the ICMR's claim to produce the Covid-19 vaccine by Aug 15 as "risky" and "impossible".

AIIMS director Randeep Guleria, who is the head of the clinical research group of the national task force on Covid, told The Indian Express, "It will be a very challenging and difficult task, considering that we have to look at both efficacy and safety of any vaccine that is introduced.

"Also, if we get the desired results, the other challenge is the process of mass production of the vaccine."

Virologist Shaheed Jameel, the chief executive of the Wellcome Trust-DBT Alliance that funds health research in India, said as quoted by the daily, "I fear the global scientific community would be laughing at us for this. It should not have happened. India is a serious player in science."

"Who is going to trust us if we behave like this? Who is going to believe us even if we indeed come up with a good vaccine tomorrow?… And I am appalled at the kind of language used in the letter. It is not a letter, it reads like a threat," he added.

Defending the claim, the ICMR said the process was “in accordance with the globally accepted norms to fast-track the vaccine development."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.